Landscape

Cisplatin-Induced Hearing Loss

Cisplatin-Induced Hearing Loss has 23 tracked records across 10 named organizations, including 4 strong-evidence records and 9 active programs. Records with caveats and trial-derived candidates remain visible for deeper review.

All Programs Therapeutics Devices

Open filtered programs

Pipeline Records

strong evidence + caveats + candidates

Strong Evidence

19 checked records with caveats

Active Programs

currently active

Marketed / Approved

commercial or approved

Organizations

companies, sponsors, and institutions

Competitive Density

35/100

organization breadth + program volume

Pipeline Velocity

37/100

active and late-stage share

Evidence Coverage

17/100

share strong evidence

Completion Signal

39/100

late-stage, approved, or marketed

Attrition Rate

26/100

share discontinued

Concentration

52/100

top-organization share

Programs by Stage

Preclinical2 · 9%

Phase 13 · 13%

Phase 1/22 · 9%

Phase 26 · 26%

Phase 33 · 13%

Phase 42 · 9%

Expanded Access1 · 4%

Interventional/NA2 · 9%

Marketed2 · 9%

Trial / Program Status

Active9 · 39%

Marketed2 · 9%

Completed4 · 17%

Discontinued6 · 26%

Unknown2 · 9%

Modality Breakdown

Small Molecule13 · 57%

Drug Delivery5 · 22%

Steroid/Anti-inflammatory3 · 13%

Diagnostic1 · 4%

Regenerative Medicine1 · 4%

Program Types

Therapeutic22 · 96%

Diagnostic1 · 4%

Top Organizations

Institution-led study12 · 52%

Otonomy3 · 13%

Acousia Therapeutics GmbH1 · 4%

Fennec Pharmaceuticals1 · 4%

hearX1 · 4%

Investigator-led study1 · 4%

Regeneron Pharmaceuticals1 · 4%

Sensorion1 · 4%

Population Tags

adult21 · 91%

cisplatin-ototoxicity20 · 87%

otoprotection7 · 30%

study-level4 · 17%

cancer3 · 13%

noise-induced3 · 13%

age-related2 · 9%

head-and-neck-cancer2 · 9%

pediatric2 · 9%

sudden2 · 9%

Strong-Evidence Programs

4 records

PEDMARK by Fennec PharmaceuticalsStrong evidence

Company: Fennec Pharmaceuticals · Marketed · Marketed

Small MoleculeMarketedMarketed98% confidence

SENS-401 (Arazasetron) by SensorionStrong evidence

Company: Sensorion · Phase 2 · Active

Small MoleculePhase 2Active94% confidence

SPI-1005 by Sound PharmaceuticalsStrong evidence

Company: Sound Pharmaceuticals · Phase 3 · Active

Small MoleculePhase 3Active90% confidence

ACOU085 by Acousia TherapeuticsStrong evidence

Company: Acousia Therapeutics GmbH · Phase 2 · Active

Small MoleculePhase 2Active93% confidence

Checked Records With Caveats

19 records

DB-020 by Regeneron and Decibel

Company: Regeneron Pharmaceuticals · Phase 1 · Completed

Drug DeliveryPhase 1Completed92% confidence

hearX hearTest

Company: hearX · Marketed · Marketed

DiagnosticMarketedMarketed90% confidence

OTO-104 (dexamethasone) by Otonomy

Company: Otonomy · Phase 3 · Discontinued

Steroid/Anti-inflammatoryPhase 3Discontinued90% confidence

OTO-6XX by Otonomy

Company: Otonomy · Preclinical · Discontinued

Regenerative MedicinePreclinicalDiscontinued84% confidence

OTO-510 by Otonomy

Company: Otonomy · Preclinical · Discontinued

Small MoleculePreclinicalDiscontinued83% confidence

NIDCD atorvastatin cisplatin otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2 · Active

Small MoleculePhase 2Active84% confidence

Intratympanic N-Acetylcysteine Cisplatin Otoprotection StudiesStatus caveat

Sponsor / Institution: Institution-led study · Phase 4 · Unknown

Small MoleculePhase 4Unknown84% confidence

NKI SOUND transtympanic sodium thiosulfate cisplatin otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 3 · Active

Drug DeliveryPhase 3Active84% confidence

TRPHARM sodium thiosulfate compassionate use programStatus caveat

Company: TRPHARM · Expanded Access · Active

Small MoleculeExpanded AccessActive84% confidence

Siriraj N-acetylcysteine cisplatin otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2 · Active

Small MoleculePhase 2Active82% confidence

University of Brasilia Ginkgo biloba cisplatin otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2 · Completed

Small MoleculePhase 2Completed82% confidence

McGill Transtympanic Ringer's Lactate Cisplatin Otoprotection StudyStatus caveat

Sponsor / Institution: Institution-led study · Phase 1/2 · Unknown

Small MoleculePhase 1/2Unknown82% confidence

City of Hope Pedmark adult testicular-cancer otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 1 · Active

Small MoleculePhase 1Active82% confidence

Sunnybrook sodium thiosulfate plus mannitol cisplatin otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 2 · Active

Small MoleculePhase 2Active82% confidence

Intratympanic sodium thiosulfate otoprotection pilot studyStatus caveat

Sponsor / Institution: Institution-led study · Interventional/NA · Discontinued

Drug DeliveryInterventional/NADiscontinued82% confidence

Meir intratympanic dexamethasone cisplatin-otoprotection studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 4 · Completed

Steroid/Anti-inflammatoryPhase 4Completed76% confidence

SNUH dexamethasone/hyaluronic-acid intratympanic delivery studyStatus caveat

Sponsor / Institution: Institution-led study · Phase 1/2 · Completed

Drug DeliveryPhase 1/2Completed76% confidence

Lactated Ringer's With Ofloxacin Cisplatin Otoprotection StudyStatus caveat

Sponsor / Institution: Institution-led study · Phase 1 · Discontinued

Drug DeliveryPhase 1Discontinued71% confidence

Moberly intratympanic dexamethasone cisplatin-otoprotection studyStatus caveat

Sponsor / Institution: Investigator-led study · Interventional/NA · Discontinued

Steroid/Anti-inflammatoryInterventional/NADiscontinued70% confidence